Evidence map›Paper›PMID 38013718›Full record

ArticleInfectious medicine2022

Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis.

Xuejuan Zhang, Mengqin Guo, Zhengwei Huang, Ying Huang, Chuanbin Wu, Xin Pan

Abstract read
In one paragraph

Article in Infectious medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. SARS-CoV-2 and reproductive system: a scientometric study.Frontiers in reproductive health · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xuejuan ZhangCollege of Pharmacy, Jinan University, Guangzhou 510632, China.
Mengqin GuoCollege of Pharmacy, Jinan University, Guangzhou 510632, China.
Zhengwei HuangCollege of Pharmacy, Jinan University, Guangzhou 510632, China.
Ying HuangCollege of Pharmacy, Jinan University, Guangzhou 510632, China.
Chuanbin WuCollege of Pharmacy, Jinan University, Guangzhou 510632, China.
Xin PanSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed great medical and economic burdens on human society, and nanotechnology is a promising technique for managing the ongoing COVID-19 pandemic. To drive further studies on anti-COVID-19 nanotechnology, this paper provides an analysis, from a bibliometric perspective, of the intersection of nanotechnology and SARS-CoV-2/COVID-19. Methods: We analyzed the 2585 publications on nanotechnology and SARS-CoV-2/COVID-19 included in the Web of Science Core Collection from January 2019 to March 2022 to determine the bibliometric landscape. The basic bibliometric characteristics are summarized in this article. Results: Our bibliometric analysis revealed that the intersection between nanotechnology and SARS-CoV-2/COVID-19 is a cutting-edge field in the science community and that the related studies were multidisciplinary in nature. Studies on the structural basis of SARS-CoV-2, SARS-CoV-2 detection assays, and mRNA vaccines against COVID-19 provided the development foundation for this field. Conclusions: The current research focuses are the development of nanomaterial-based vaccines and SARS-CoV-2 detection methods, and the design of nanomedicines carrying SARS-CoV-2 inhibitors is a relatively burgeoning frontier. In summary, this bibliometric analysis of the intersection of nanotechnology and SARS-CoV-2/COVID-19 highlights the current research focuses of this field to inspire future studies on anti-COVID-19 nanotechnologies.

Indexed as

Bibiometric analysisCoronavirus disease 2019, COVID-19COVID-19Nano technologySARS-CoV-2Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2Web of Science

Identifiers

PMID38013718
PMCPMC9233748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.